---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-250665"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2022-09-26T23:59:59+00:00"
generated_at: "2026-06-23T07:30:35.690166+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Phathom Pharmaceuticals appoints James Topper, M.D., Ph.D. to Board of Directors

## Summary
- James Topper appointed as Class III director effective September 22, 2022; will serve on nominating and corporate governance committee.
- Topper previously served on board from January 2018 to May 2021; currently Managing General Partner at Frazier Life Sciences.
- Granted option to purchase 20,000 shares vesting over three years; cash compensation per Non-Employee Director Compensation Program.
- Board determined Topper meets Nasdaq independence requirements; no related person transactions.

## SEC filing metadata
- accession: 0001193125-22-250665
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2022-09-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312522250665/0001193125-22-250665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312522250665/d361727d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-250665
- JSON: https://secwatch.observer/filing/0001193125-22-250665.json
- Plain text: https://secwatch.observer/filing/0001193125-22-250665.txt

## Key facts
- Executive change
  James Topper, M.D., Ph.D. was appointed as Class III Director at Phathom Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: On September 22, 2022, the board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed James Topper, M.D., Ph.D. to the Board as a Class III director, effective immediately, with an initial term expiring at the 2025 annual meeting of stockholders of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783183/000119312522250665/0001193125-22-250665-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.